[{"id":"47b96ada-e4a0-4b3c-9de2-04691e9ba258","acronym":"LAMP-2","url":"https://clinicaltrials.gov/study/NCT06889168","created_at":"2025-06-07T14:47:25.914Z","updated_at":"2025-06-07T14:47:25.914Z","phase":"Phase 1","brief_title":"Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)","source_id_and_acronym":"NCT06889168 - LAMP-2","lead_sponsor":"Columbia University","biomarkers":" VEGFD","pipe":"","alterations":" ","tags":["VEGFD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2025-05-31"},{"id":"a8dbbb89-8bb1-4f12-ad96-eb67e83dce09","acronym":"","url":"https://clinicaltrials.gov/study/NCT00265798","created_at":"2021-01-18T00:54:12.869Z","updated_at":"2025-02-25T13:47:55.628Z","phase":"Phase 2","brief_title":"Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate","source_id_and_acronym":"NCT00265798","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KIT","pipe":" | ","alterations":" KIT expression","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • imatinib • sunitinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 09/14/2005","start_date":" 09/14/2005","primary_txt":" Primary completion: 02/11/2010","primary_completion_date":" 02/11/2010","study_txt":" Completion: 03/08/2025","study_completion_date":" 03/08/2025","last_update_posted":"2025-02-20"},{"id":"d77f7e27-d759-4800-bb9d-f2404753c9ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT06222593","created_at":"2024-01-24T15:19:20.942Z","updated_at":"2025-02-25T14:10:34.092Z","phase":"Phase 1/2","brief_title":"Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination with Sunitinib in Patients with TKIs-resistant RCC","source_id_and_acronym":"NCT06222593","lead_sponsor":"State University of New York at Buffalo","biomarkers":" AR • KLK2","pipe":" | ","alterations":" AR expression • KLK2 expression","tags":["AR • KLK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR expression • KLK2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • bicalutamide"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 10/01/2024","start_date":" 10/01/2024","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2025-02-17"},{"id":"63139aa8-19bf-4602-a810-5c7110a10962","acronym":"","url":"https://clinicaltrials.gov/study/NCT04423185","created_at":"2021-01-18T21:18:39.174Z","updated_at":"2025-02-25T15:26:22.079Z","phase":"Phase 2","brief_title":"PLATFORM Study of Precision Medicine for Rare Tumors","source_id_and_acronym":"NCT04423185","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification","tags":["EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • imatinib • Tyvyt (sintilimab) • Alecensa (alectinib) • Zejula (niraparib) • Irene (pyrotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 770","initiation":"Initiation: 08/15/2020","start_date":" 08/15/2020","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-11"},{"id":"0adc2fbc-6b3e-4f34-8de8-ac2947fe1dfb","acronym":"","url":"https://clinicaltrials.gov/study/NCT00070499","created_at":"2021-01-18T00:10:44.565Z","updated_at":"2025-02-25T16:21:43.510Z","phase":"Phase 2","brief_title":"Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia","source_id_and_acronym":"NCT00070499","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 406","initiation":"Initiation: 08/15/2004","start_date":" 08/15/2004","primary_txt":" Primary completion: 11/01/2010","primary_completion_date":" 11/01/2010","study_txt":" Completion: 02/22/2025","study_completion_date":" 02/22/2025","last_update_posted":"2024-12-27"},{"id":"f33d52c2-9a8f-4b5c-acef-4121e6304fc8","acronym":"CA209-982","url":"https://clinicaltrials.gov/study/NCT03583086","created_at":"2021-01-18T17:37:36.257Z","updated_at":"2025-02-25T14:27:15.271Z","phase":"Phase 1/2","brief_title":"Phase I/II Eval Safety \u0026 Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors","source_id_and_acronym":"NCT03583086 - CA209-982","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" EGFR • PD-L1 • BRAF • ROS1","pipe":"","alterations":" ","tags":["EGFR • PD-L1 • BRAF • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Fumena (vorolanib)"],"overall_status":"Completed","enrollment":" Enrollment 88","initiation":"Initiation: 07/10/2018","start_date":" 07/10/2018","primary_txt":" Primary completion: 02/21/2024","primary_completion_date":" 02/21/2024","study_txt":" Completion: 04/27/2024","study_completion_date":" 04/27/2024","last_update_posted":"2024-10-08"},{"id":"90e2c2df-d5c6-4f93-8b0d-0ff266e30b82","acronym":"","url":"https://clinicaltrials.gov/study/NCT01306045","created_at":"2021-01-18T05:18:49.422Z","updated_at":"2024-07-02T16:35:10.788Z","phase":"Phase 2","brief_title":"Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies","source_id_and_acronym":"NCT01306045","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • BRAF","pipe":" | ","alterations":" EGFR mutation","tags":["EGFR • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • sunitinib • lapatinib • Koselugo (selumetinib) • MK-2206"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 647","initiation":"Initiation: 02/08/2011","start_date":" 02/08/2011","primary_txt":" Primary completion: 02/12/2014","primary_completion_date":" 02/12/2014","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-04-09"},{"id":"cb8d2781-175e-47d3-a3e8-c2f88771d5b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT00381641","created_at":"2023-11-22T18:15:18.641Z","updated_at":"2024-07-02T16:35:11.050Z","phase":"Phase 2","brief_title":"Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery","source_id_and_acronym":"NCT00381641","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RET","pipe":"","alterations":" ","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 08/08/2006","start_date":" 08/08/2006","primary_txt":" Primary completion: 12/31/2016","primary_completion_date":" 12/31/2016","study_txt":" Completion: 03/08/2025","study_completion_date":" 03/08/2025","last_update_posted":"2024-04-08"},{"id":"f0120f59-10df-43f7-b5bb-987a4f3afad2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05493215","created_at":"2022-08-09T17:04:45.434Z","updated_at":"2024-07-02T16:35:12.164Z","phase":"Phase 2","brief_title":"Imatinib TDM in GIST","source_id_and_acronym":"NCT05493215","lead_sponsor":"Reema A. Patel","biomarkers":" KIT • PDGFRA","pipe":" | ","alterations":" KIT mutation • PDGFRA D842V • PDGFRA mutation","tags":["KIT • PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • PDGFRA D842V • PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 03/26/2024","start_date":" 03/26/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-01"},{"id":"47aa2393-a124-415e-825e-d17be7197efa","acronym":"NCI-2018-00192","url":"https://clinicaltrials.gov/study/NCT03463460","created_at":"2021-01-18T17:04:23.138Z","updated_at":"2024-07-02T16:35:14.545Z","phase":"Phase 2","brief_title":"Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer","source_id_and_acronym":"NCT03463460 - NCI-2018-00192","lead_sponsor":"Dwight Owen","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • sunitinib"],"overall_status":"Suspended","enrollment":" Enrollment 30","initiation":"Initiation: 06/19/2018","start_date":" 06/19/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-15"},{"id":"5e15875a-b705-45d9-82c2-48412b14a477","acronym":"","url":"https://clinicaltrials.gov/study/NCT04798781","created_at":"2021-03-15T15:53:52.732Z","updated_at":"2024-07-02T16:35:15.900Z","phase":"Phase 2","brief_title":"Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma","source_id_and_acronym":"NCT04798781","lead_sponsor":"Andrew Hendifar, MD","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • telatinib (BAY 57- 9352)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 17","initiation":"Initiation: 07/28/2021","start_date":" 07/28/2021","primary_txt":" Primary completion: 02/14/2024","primary_completion_date":" 02/14/2024","study_txt":" Completion: 02/14/2025","study_completion_date":" 02/14/2025","last_update_posted":"2024-03-07"},{"id":"afe5eda5-b0b2-4528-9023-e2c1d7118027","acronym":"","url":"https://clinicaltrials.gov/study/NCT05905887","created_at":"2023-06-15T17:08:41.962Z","updated_at":"2024-07-02T16:35:17.151Z","phase":"Phase 2","brief_title":"Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor","source_id_and_acronym":"NCT05905887","lead_sponsor":"Asan Medical Center","biomarkers":" KIT • PDGFRA • ANO1","pipe":" | ","alterations":" KIT mutation","tags":["KIT • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • imatinib • sunitinib • AiTan (rivoceranib) • Stivarga (regorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 09/06/2023","start_date":" 09/06/2023","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-02-28"},{"id":"afe413d7-7e85-457e-9af3-9c556a34d9ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT01396408","created_at":"2021-01-18T05:44:09.814Z","updated_at":"2024-07-02T16:35:17.762Z","phase":"Phase 2","brief_title":"A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours","source_id_and_acronym":"NCT01396408","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" PTEN • STK11 • NF1","pipe":" | ","alterations":" EGFR mutation • PTEN mutation • NF1 mutation • MTOR mutation • AKT1 amplification","tags":["PTEN • STK11 • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • PTEN mutation • NF1 mutation • MTOR mutation • AKT1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • temsirolimus"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 137","initiation":"Initiation: 02/09/2012","start_date":" 02/09/2012","primary_txt":" Primary completion: 07/06/2015","primary_completion_date":" 07/06/2015","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-02-26"},{"id":"0bf314c0-3f99-4411-8621-e2f140cb0c09","acronym":"ImadGist","url":"https://clinicaltrials.gov/study/NCT02260505","created_at":"2021-01-18T10:37:12.302Z","updated_at":"2024-07-02T16:35:24.473Z","phase":"Phase 3","brief_title":"Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)","source_id_and_acronym":"NCT02260505 - ImadGist","lead_sponsor":"Centre Leon Berard","biomarkers":" KIT","pipe":"","alterations":" ","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Completed","enrollment":" Enrollment 136","initiation":"Initiation: 12/24/2014","start_date":" 12/24/2014","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2024-01-05"},{"id":"0eefbaf9-a4ea-454b-868c-1b99280a8dd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01541709","created_at":"2021-01-18T06:30:56.005Z","updated_at":"2024-07-02T16:35:24.757Z","phase":"Phase 2","brief_title":"Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI","source_id_and_acronym":"NCT01541709","lead_sponsor":"Asan Medical Center","biomarkers":" KIT • ANO1","pipe":" | ","alterations":" KIT mutation • KIT exon 9 mutation","tags":["KIT • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT exon 9 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 03/01/2012","start_date":" 03/01/2012","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-01-01"},{"id":"4c2f1c18-6e61-4a09-9dd2-0ccca96142b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03944304","created_at":"2021-01-18T19:25:15.034Z","updated_at":"2024-07-02T16:35:24.855Z","phase":"Phase 2","brief_title":"Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib.","source_id_and_acronym":"NCT03944304","lead_sponsor":"Asan Medical Center","biomarkers":" KIT • PDGFRA • ANO1","pipe":" | ","alterations":" KIT mutation","tags":["KIT • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • imatinib • sunitinib • Stivarga (regorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 05/27/2019","start_date":" 05/27/2019","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2024-01-01"},{"id":"4940e693-9465-46a4-adde-f09648b1d496","acronym":"JAVELIN Renal 101","url":"https://clinicaltrials.gov/study/NCT02684006","created_at":"2021-01-17T17:21:28.108Z","updated_at":"2024-07-02T16:35:25.303Z","phase":"Phase 3","brief_title":"A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)","source_id_and_acronym":"NCT02684006 - JAVELIN Renal 101","lead_sponsor":"Pfizer","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • Bavencio (avelumab) • axitinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 888","initiation":"Initiation: 03/23/2016","start_date":" 03/23/2016","primary_txt":" Primary completion: 08/31/2023","primary_completion_date":" 08/31/2023","study_txt":" Completion: 05/21/2024","study_completion_date":" 05/21/2024","last_update_posted":"2023-12-22"},{"id":"ac38e7b9-aa0f-4c10-b443-8463b2fb4d72","acronym":"EDI-PIO","url":"https://clinicaltrials.gov/study/NCT02852486","created_at":"2022-04-24T08:57:48.167Z","updated_at":"2024-07-02T16:35:27.180Z","phase":"Phase 2","brief_title":"Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response","source_id_and_acronym":"NCT02852486 - EDI-PIO","lead_sponsor":"University of Campinas, Brazil","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 06/22/2016","start_date":" 06/22/2016","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 02/01/2024","study_completion_date":" 02/01/2024","last_update_posted":"2023-12-04"},{"id":"d4088676-34af-47b3-9b35-79e3fba11bee","acronym":"","url":"https://clinicaltrials.gov/study/NCT03193281","created_at":"2021-01-18T15:44:28.970Z","updated_at":"2024-07-02T16:35:27.695Z","phase":"Phase 2","brief_title":"KISS Study: Kinase Inhibition With Sprycel Start up","source_id_and_acronym":"NCT03193281","lead_sponsor":"University of Auckland, New Zealand","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 91","initiation":"Initiation: 07/17/2017","start_date":" 07/17/2017","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-11-29"},{"id":"ff971a31-4620-40ce-aa35-33a25eb28431","acronym":"","url":"https://clinicaltrials.gov/study/NCT02413736","created_at":"2021-01-18T11:31:48.616Z","updated_at":"2024-07-02T16:35:29.677Z","phase":"Phase 3","brief_title":"Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST","source_id_and_acronym":"NCT02413736","lead_sponsor":"Heikki Joensuu","biomarkers":" KIT • PDGFRA • ANO1","pipe":" | ","alterations":" KIT mutation • PDGFRA mutation","tags":["KIT • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 255","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2033","study_completion_date":" 05/01/2033","last_update_posted":"2023-11-09"},{"id":"a0b3f6c9-63cb-46f1-bf91-469d10920061","acronym":"","url":"https://clinicaltrials.gov/study/NCT03262974","created_at":"2021-01-18T16:07:06.270Z","updated_at":"2024-07-02T16:35:31.295Z","phase":"","brief_title":"Effect of Pharmacogenetics on Imatinib Plasma Level and Response","source_id_and_acronym":"NCT03262974","lead_sponsor":"Assiut University","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 10/29/2017","start_date":" 10/29/2017","primary_txt":" Primary completion: 10/01/2023","primary_completion_date":" 10/01/2023","study_txt":" Completion: 10/01/2023","study_completion_date":" 10/01/2023","last_update_posted":"2023-10-27"},{"id":"6930bd13-a689-4284-b6bf-affbebb0e167","acronym":"","url":"https://clinicaltrials.gov/study/NCT05366816","created_at":"2022-05-09T11:56:34.398Z","updated_at":"2024-07-02T16:35:32.170Z","phase":"Phase 2","brief_title":"ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST","source_id_and_acronym":"NCT05366816","lead_sponsor":"University of Miami","biomarkers":" KIT","pipe":" | ","alterations":" KIT exon 13 mutation • KIT exon 17 mutation","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT exon 13 mutation • KIT exon 17 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • Stivarga (regorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 10/17/2023","start_date":" 10/17/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2023-10-23"},{"id":"9029b63b-49b7-4f5b-bf2d-d1dd5f6be242","acronym":"","url":"https://clinicaltrials.gov/study/NCT04006769","created_at":"2021-01-18T19:41:21.824Z","updated_at":"2024-07-02T16:35:32.887Z","phase":"Phase 1","brief_title":"Entacapone Combination With Imatinib for Treatment of GIST","source_id_and_acronym":"NCT04006769","lead_sponsor":"Xiangya Hospital of Central South University","biomarkers":" KIT • FTO","pipe":" | ","alterations":" KIT mutation • KIT expression • FTO expression","tags":["KIT • FTO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT expression • FTO expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • sunitinib"],"overall_status":"Completed","enrollment":" Enrollment 5","initiation":"Initiation: 10/30/2020","start_date":" 10/30/2020","primary_txt":" Primary completion: 08/31/2022","primary_completion_date":" 08/31/2022","study_txt":" Completion: 08/31/2022","study_completion_date":" 08/31/2022","last_update_posted":"2023-10-18"},{"id":"2b124228-ef48-45e7-9ae0-0513192b4cf6","acronym":"CARCML","url":"https://clinicaltrials.gov/study/NCT05282108","created_at":"2022-03-16T15:54:08.773Z","updated_at":"2024-07-02T16:35:36.097Z","phase":"","brief_title":"Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia","source_id_and_acronym":"NCT05282108 - CARCML","lead_sponsor":"Hikma Pharmaceuticals LLC","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 07/20/2022","start_date":" 07/20/2022","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2023-09-22"}]